Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Appointed director
Quarterly results
Diffusion Pharmaceuticals Inc. (DFFN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/16/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/21/2022 8-K Quarterly results
Docs: "Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update ● Altitude Trial Dosing Expected To Be Completed in 2Q2022; mid-2022 for ILD-DLCO Trial ● Phase 2 Hypoxic Solid Tumor Study Protocol Submission Planned to Support 2H22 Study Start ● $37.3M in Cash & Cash Equivalents as of Year-End; Expected to Fund Operations Through 2023 CHARLOTTESVILLE, Va., March 21, 2022 -- Diffusion Pharmaceuticals Inc. , an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced financial results for 2021 and provided a business update. Corporate Strategy and Events Business and financial highlights during 2021 and 2022 year-to-date include: Declared Lead Dev..."
11/10/2021 8-K Quarterly results
Docs: "Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update ● Announces Intent to Develop TSC to Treat Hypoxic Tumors ● Altitude Trial Expected to Commence in November 2021 ● ILD-DLCO Trial Expected to Commence in Late December 2021 CHARLOTTESVILLE, Va., November 10, 2021 -- Diffusion Pharmaceuticals Inc. , a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced financial results for the third quarter of 2021 and provided a business update. “We believe this is an exciting time for Diffusion Pharmaceuticals. The data we have obtained over the last year from our TCOM and COVID-19 studies have enhanced our understanding of TSC dosing and its m..."
08/13/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
03/17/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates"
08/10/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
Docs: "Diffusion Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update"
03/18/2020 8-K Quarterly results
Docs: "Separation Agreement, by and between Diffusion Pharmaceuticals Inc. and John L. Gainer",
"Consulting Agreement, by and between Diffusion Pharmaceuticals Inc. and John L. Gainer",
"Diffusion Pharmaceuticals Announces Retirement of Chief Science Officer John L. Gainer",
"Diffusion Pharmaceuticals Reports 2019 Financial Results and Provides Business Update"
11/12/2019 8-K Quarterly results
Docs: "Diffusion Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update"
05/09/2019 8-K Quarterly results
Docs: "Diffusion Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update"
11/14/2018 8-K Quarterly results
Docs: "Diffusion Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update"
05/10/2018 8-K Quarterly results
Docs: "Diffusion Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update ● Patient screening and enrollment are underway in Phase 3 inoperable GBM brain cancer trial ● Key U.S. Patent Issued ● Clinical trial preparations are ongoing for Phase 2 trial with TSC in stroke CHARLOTTESVILLE, Va. – Diffusion Pharmaceuticals Inc. , a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients using the novel small molecule trans sodium crocetinate in conjunction with standard radiation and chemotherapy, reports financial results for the three months ended March 31, 2018 and provides a business update. “During the first quarter patients continued to be screened and enrolled into our lead clinical program, the IN vesti..."
04/03/2018 8-K Quarterly results
Docs: "Diffusion Pharmaceuticals Reports 2017 Financial Results and Provides Business Update ● Patient Enrollment in Phase 3 Inoperable GBM Brain Cancer Trial Underway ● Raised $12 Million in Underwritten Public Offering ● Preparing to Commence Clinical Trial with TSC in Stroke ● Expanded Intellectual Property Portfolio with New Key Patents CHARLOTTESVILLE, Va. – Diffusion Pharmaceuticals Inc. , a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients using the novel small molecule trans sodium crocetinate in conjunction with standard radiation and chemotherapy, reports 2017 financial results and provides a business update. Diffusion’ s lead clinical trial program, the IN vestigation of T SC A gainst C ancerous T umors trial, is a ..."
11/13/2017 8-K Quarterly results
Docs: "Diffusion Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update ● FDA Clears Phase 3 Protocol for Patient Enrollment in GBM Brain Cancer Trial ● “First Patient In” Expected this Year ● Company Charter Amendment Addresses Nasdaq Listing Issue ● Additions to Board and Management Strengthen Company Buildout CHARLOTTESVILLE, Va. – Diffusion Pharmaceuticals Inc. , a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients using the novel small molecule trans sodium crocetinate in conjunction with standard radiation and chemotherapy, today reported financial results for the three and nine months ended September 30, 2017 and provided a business update. David Kalergis, Chairman and Chief Executive O..."
08/14/2017 8-K Quarterly results
05/15/2017 8-K Quarterly results
Docs: "Stephanie Carrington ICR Inc."
05/15/2017 8-K Quarterly results
Docs: "Stephanie Carrington ICR Inc."
11/14/2016 8-K Quarterly results
Docs: "Press release dated November 14, 2016, announcing financial results for the third quarter ended September 30, 2016"
08/15/2016 8-K Quarterly results
Docs: "Press release dated August 15, 2016, announcing financial results for the second quarter ended June 30, 2016"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy